Botanix Pharmaceuticals Ltd
ASX:BOT

Watchlist Manager
Botanix Pharmaceuticals Ltd Logo
Botanix Pharmaceuticals Ltd
ASX:BOT
Watchlist
Price: 0.395 AUD 3.95% Market Closed
Market Cap: 717.9m AUD
Have any thoughts about
Botanix Pharmaceuticals Ltd?
Write Note

Botanix Pharmaceuticals Ltd
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Botanix Pharmaceuticals Ltd
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
Botanix Pharmaceuticals Ltd
ASX:BOT
Capital Expenditures
-AU$18m
CAGR 3-Years
-1 195%
CAGR 5-Years
-323%
CAGR 10-Years
N/A
Recce Pharmaceuticals Ltd
ASX:RCE
Capital Expenditures
-AU$101.8k
CAGR 3-Years
-10%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
Mayne Pharma Group Ltd
ASX:MYX
Capital Expenditures
-AU$20.9m
CAGR 3-Years
6%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Neuren Pharmaceuticals Ltd
ASX:NEU
Capital Expenditures
-AU$25k
CAGR 3-Years
-46%
CAGR 5-Years
-16%
CAGR 10-Years
5%
Probiotec Ltd
ASX:PBP
Capital Expenditures
-AU$10.8m
CAGR 3-Years
-47%
CAGR 5-Years
0%
CAGR 10-Years
-5%
Arovella Therapeutics Ltd
ASX:ALA
Capital Expenditures
-AU$129.3k
CAGR 3-Years
37%
CAGR 5-Years
38%
CAGR 10-Years
N/A
No Stocks Found

Botanix Pharmaceuticals Ltd
Glance View

Market Cap
715m AUD
Industry
Pharmaceuticals

Botanix Pharmaceuticals Ltd. engages in the development of therapeutics for the treatment of skin diseases. The company is headquartered in Perth, Western Australia. The firm's product pipelines are based on drug delivery technology known as Permetrex. Its product pipeline consists of three clinical programs, which are using synthetic cannabidiol in the topical treatment of serious skin diseases and for antimicrobial applications. Its product pipeline includes BTX 1503 Gel, BTX 1702 Solution and BTX 1801 Ointment. Its BTX1503 Gel is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX 1702 Solution is used for the treatment of papulopustular rosacea. Its BTX 1801 Ointment is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus (MRSA). The firm also has a chemistry program to identify, synthesize and test chemical entities that are related to naturally occurring cannabinoids.

BOT Intrinsic Value
1.114 AUD
Undervaluation 65%
Intrinsic Value
Price

See Also

What is Botanix Pharmaceuticals Ltd's Capital Expenditures?
Capital Expenditures
-18m AUD

Based on the financial report for Jun 30, 2024, Botanix Pharmaceuticals Ltd's Capital Expenditures amounts to -18m AUD.

What is Botanix Pharmaceuticals Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-323%

Over the last year, the Capital Expenditures growth was -155%. The average annual Capital Expenditures growth rates for Botanix Pharmaceuticals Ltd have been -1 195% over the past three years , -323% over the past five years .

Back to Top